Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | PLAT | P00750 | 15/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15941963 | 0.85 | PLAT (0.49) | HCAR2PLAT | |
| Hydrochloric Acid SCHEMBL29918467 | 0.84 | PLAT (0.48) | HCAR2PLAT | |
| Hydrochloric Acid SCHEMBL31554770 | 0.84 | PLAT (0.48) | HCAR2PLAT | |
| Cadaverine Tartrate SCHEMBL30751761 | 0.84 | HCAR2 (0.45) | HCAR2PLATHDAC4 | |
| SCHEMBL5445602 | 0.75 | HCAR2 (0.42) | HCAR2HDAC4 | |
| Trifluoroacetic Acid SCHEMBL20424356 | 0.74 | HRH4 (0.46) | HRH4HRH3 | |
| SCHEMBL12802841 | 0.74 | — | — | |
| Trifluoroacetic Acid SCHEMBL26600330 | 0.73 | HTR2C (0.54) | HRH4HRH3 | |
| Hydrochloric Acid SCHEMBL16827936 | 0.71 | MEN1 (0.38) | PLAT | |
| SCHEMBL8021529 | 0.70 | PLAT (0.42) | PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117847-A1 | N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | CHAMBERS MARK S | 2007-05-24 | — | — | US | disclosed |
| US-7153868-B2 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | MERCK SHARP & DOHME LTD. | 2006-12-26 | — | — | US | disclosed |
| US-20040002504-A1 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | MERCK SHARP & DOHME LTD. (GB) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002504-A1 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | KCNH3, KCNH2, KCNK3 | HCAR2 721/4885PLAT 4817/4885HRH4 82/4885 |
| US-20070117847-A1 | N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | TACR2, KCNK3, KCNH3 | HCAR2 939/4885PLAT 4639/4885HRH4 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.